

Scott Requadt

CEO at Consulate General of Canada (CTA Boston)

Boston, MA, US

Scott Requadt has operating and investment experience in the biopharmaceutical industry including therapeutics, medtech and diagnostics.

Biography

Scott Requadt, JD, MBA, is the CEO of Talaris Therapeutics and serves on the Board of Directors. Scott has over 17 years of operating and investment experience in the biopharmaceutical industry. Scott was previously a Managing Director of Clarus (now Blackstone Life Sciences), where he sourced, led and managed multiple investments for Clarus spanning therapeutics, medtech and diagnostics. He currently serves on the Board of Directors of ESSA Pharmaceuticals (Nasdaq: EPIX), and previously served on the Boards of Edev S.a.r.l., AvroBio (Nasdaq: AVRO), VBI Vaccines (Nasdaq: VBIV) and TyRx, Inc. Scott remains a Venture Partner advisor to Blackstone Life Sciences. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. Prior to TransForm, Scott was an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a J.D. from University of Toronto and an MBA from Harvard Business School, where he was a Baker Scholar.

Industry Expertise

Biotechnology, Pharmaceuticals

Areas of Expertise

Entrepreneurship, Corporate Development, Life Sciences, Biotechnology, Venture Capital, Pharmaceutical Industry

Education

Harvard Business School

M.B.A. Business Administration

University of Toronto Law School

L.L.B.

McGill University

B.Comm Economics & Finance

[Please click here to view the full profile.](#)

This profile was created by [Expertfile.](#)